BOSTON, May  07, 2026  (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CUE Appoints New CEO and Issues Significant Equity Awards

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BOSTON, May  07, 2026  (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cue Biopharma appointed Dr. Shao-Lee Lin as CEO and issued substantial equity awards. This leadership change could help enhance strategic direction and boost investor confidence as the firm progresses with its clinical-stage assets.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CUE granted inducement equity awards to seven new employees.</li><li>Dr. Shao-Lee Lin appointed as CEO with significant stock options.</li><li>Total options awarded: over 1.17 million shares at $30.42 each.</li><li>Inducement grants are tied to Nasdaq compliance regulations.</li><li>CUE&#039;s lead candidate is advancing towards Phase 1 trials.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cue Biopharma (CUE)</strong>: CUE&#039;s leadership and pipeline developments indicate potential upward trajectory.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it involves a leadership change and equity awards. Such factors can significantly influence investor sentiment and stock valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CUE&#039;s stock may react positively to CEO appointment and equity grants.</li><li>Upcoming Phase 1 trials for CUE-401 could further influence stock value.</li><li>Successful advancement in immunological therapies may attract additional investment.</li><li>Nasdaq compliance could stabilize share performance through confident market perception.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Dr. Shao-Lee Lin’s stock options total 655,074 shares.</li><li>Total options granted to new employees exceed 1.17 million shares.</li><li>Equity awards priced at $30.42 per share, closing price on May 1, 2026.</li><li>Stock options will vest over four years based on employment.</li><li>CUE&#039;s lead asset is a novel anti-IgE antibody in Phase 2 development.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying CUE for potential short-term gains following leadership transition.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>BOSTON, May  07, 2026  (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CUE">CUE</a>), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company's 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>  <p>The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company's common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock units with respect to 327,537 shares of common stock. Dr. Lin's option will vest in equal, monthly installments over four years from her start date, subject to continued employment with the Company through each applicable vesting date. Dr. Lin's restricted stock unit award was fully vested upon grant.</p>  <p>The inducement grants made to the six other new employees consisted of (i) non-statutory stock options to purchase an aggregate of 518,599 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company's common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock unit awards with respect to an aggregate of 327,534 shares of common stock. The option grants will vest in equal, quarterly installments over four years from each employee's start date, subject to each employee's continued employment with the Company through each applicable vesting date. The restricted stock unit awards were fully vested upon grant.</p>  <p><strong>About Cue Biopharma </strong><br></br>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CUE">CUE</a>) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT<sup>&#xAE;</sup> platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.</p>  <p><strong>Investor and Media Contact</strong><br></br><a href="https://www.globenewswire.com/Tracker?data=GVM2FMW7dSooFbhAMOwGQTK1NPc8N1X53wF6JM5dcnbOkiZwIOhjoeuRhFwFWzKKi02qYBdNfoj9lH7j82LX4w==" rel="nofollow" target="_blank">ir@cuebio.com</a><br></br>Cue Biopharma, Inc.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNjE4NCM3NTkxODIzIzIwOTI2OTI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YjdmNzI1MDEtYzIyZC00ZTM5LWIzNGUtZjk0MWNkMWYxZTU4LTExMDQyNjMtMjAyNi0wNS0wNy1lbg==/tiny/Cue-Biopharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/10541379-34cc-4869-a26f-fd99feead42a"><img src="https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg" border="0" width="150" height="55" alt="Primary Logo"></img></a></p>

Cue Biopharma appointed Dr. Shao-Lee Lin as CEO and issued substantial equity awards. This leadership change could help enhance strategic direction and boost investor confidence as the firm progresses with its clinical-stage assets.

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News